Showing papers in "Drug Discovery Today in 2009"

TL;DR: The fewer aromatic rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addition, more than three aromatic rings in a molecule correlates with poorer compound developability and, thus, an increased risk of attrition in development.

TL;DR: This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging.

TL;DR: The current developments in homology modeling are reported, the successful application of this technique to different stages of the drug discovery process is reviewed, and in silico modeling limitations are discussed.

TL;DR: A reverse pharmacology approach, inspired by traditional medicine and Ayurveda, can offer a smart strategy for new drug candidates to facilitate discovery process and also for the development of rational synergistic botanical formulations.

TL;DR: Three current 3D cell culture technologies are presented in this review: membranes, sponges/gels and microcarriers and are evaluated for usefulness in modern automated cell-based screening equipment.

TL;DR: This review focuses on the role of the HATs p300, CBP, PCAF and GCN5 in different diseases and the development of small-molecule inhibitors of these enzymes as potential drugs.

TL;DR: The necessary safety data is now emerging to show that new generation adjuvants can be safely used in diverse human populations, and in combination with data showing the positive contributions of the adjuvant to the immune response, this safety data should allow several vaccines containing novel adjuvant to obtain licensure within the next few years.

TL;DR: Protein-protein interfaces are highly attractive targets for drug discovery because they are involved in a large number of disease pathways where therapeutic intervention would bring widespread benefit and drug discovery methods that simultaneously target several small pockets at the protein-protein interface are likely to increase the chances of success.

TL;DR: An expanded view on the application of predictive strategies and technologies to early safety decisions and suggestions to narrow the focus for improving preclinical safety testing to the problems that contribute most to adverse drug reactions are offered.

TL;DR: Computational modeling has been utilized extensively to make crucial advances in understanding membrane protein structure and function.

TL;DR: This review considers the PTMs most often associated with therapeutic proteins and focuses upon more recent advances in engineering PTMs with the aim of improving the application-relevant functional characteristics of these drugs.

TL;DR: It is concluded, from a comparison of the different approaches, that a combination of methods is likely to provide the most reliable solution to the problem of finding the right protein conformation for a given ligand.

TL;DR: Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining growing importance in oncology and novel classic and unconventional Pt(II) and Pt(IV) complexes have been introduced in therapy or are presently in advanced clinical trials.

TL;DR: It might be possible for the DHP motif to serve as a scaffold for other pharmacological applications, particularly as antimycobacterial and anticonvulsant agents.

TL;DR: Recent progress and challenges in the field in this highly competitive area of drug discovery are discussed and one of the first novel mechanisms of action for the treatment for pain for many years may be offered.

TL;DR: This work reviews recent advances in both arraying strategies based on nano/ microfluidics and novel nano/microfluidic devices with high analytical throughput rates.

TL;DR: The realised potential of plant-produced vaccines is discussed, together with future prospects for production and registration.

TL;DR: In this review, a historical perspective of how rapidly fragment-based drug discovery has developed is given and a number of clinical compounds discovered using this approach are described.

TL;DR: This review analyses a representative set of 23 published FBDD studies that describe how low molecular weight fragments are being identified and efficiently transformed into higher molecular weight drug candidates.

TL;DR: In response to the huge demand of data mining for target discovery in the 'omics' era, this review explicates various data mining approaches and their applications to target discovery with emphasis on text and microarray data analysis.

TL;DR: Mitochondrion-targeted agents such as BA hold great promise as a novel approach to overcome certain forms of drug resistance in human cancers.

TL;DR: In this article, the unique physiological and pharmacological properties of the multitude of GABA(A) receptor subtypes present in the central nervous system (CNS) have been discussed, making this receptor an important target for novel rational drug therapy.

TL;DR: Evaluating FBDD examples from the literature using LE and fit quality, it is found that, in general, the LEs of starting fragments are greater than those of larger, more elaborated, structures.

TL;DR: Virulence factors of fungi and their inhibitors have, at least to some extent, been discovered and characterized and should provide new options for the development of potential antifungal therapeutics.

TL;DR: Initial investigations reveal a surprising heterogeneity among SARs and shed light on the relationship between 'global' and 'local' SAR features.

TL;DR: The histamine H3 receptor plays a regulatory role in the pre-synaptic release of histamine and other neurotransmitters, making it an attractive target for CNS indications including cognitive disorders, narcolepsy, ADHD and pain.

TL;DR: Nuclear magnetic resonance, surface plasmon resonance, and fluorescence spectroscopy (particularly fluorescence anisotropy, fluorescence lifetime) are techniques often applied to fragment screening.

TL;DR: Various co-development strategies for the formulation of cytotoxic drugs with this multi-drug resistance (MDR) reversing additives using pharmaceutical excipients to inhibit P-gp and enhance drug permeability are focused on.

TL;DR: This review aims to recapitulate efforts in the pharmaceutical industry to address GPCR-directed drug discovery in a target-class-directed platform approach: establishing G PCR-specific biological assay panels and creating computational chemistry methods for finding and optimizing small molecules modulating the activity of GPCRs.

TL;DR: The conventional empiric approach to vaccine development is being replaced by vaccine design, and the recent development of synthetic genomics may provide a further opportunity to design vaccines.